Aberdeen PhD: Developing an Aptamer-Based PET Tracer for TDP-43 Proteinopathies

Aberdeen PhD: Developing an Aptamer-Based PET Tracer for TDP-43 Proteinopathies

Research focus and application timing

This four-year Aberdeen EastBio doctorate asks whether a pathology-binding aptamer can become a useful PET imaging probe, bridging radiochemistry and human neuropathology. Existing tissue detection is a credible starting point, but access to the living brain and quantitative imaging remain distinct hurdles. The project directory gives a deadline of 16 November 2026, 23:59 GMT for the complete application and both references; current acceptance status has not been verified. International applicants, including applicants from China subject to individual eligibility assessment, can compete; the 30% cap applies to annual EASTBIO awards, not an individual probability of success. The 21 October EastBio FAQ explicitly waives the overseas-fee top-up for successful international candidates. The main decision is whether the available chemistry, tissue and imaging support make an achievable PhD, not whether a clinically approved tracer is already in hand. Current recruitment; International award rules

Research Question and Doctoral Work

TDP-43 aggregation is associated with ALS, FTD, LATE and co-pathology in other neurodegenerative disease. The advertised starting point is a proprietary aptamer reported to recognise pathological aggregates and early changes associated with loss-of-function signatures. The PhD explores PET-compatible probe development across radiochemistry, medicinal chemistry and neuroscience. Advertised tasks cover conjugate characterisation, non-radioactive stability assessment, radiolabelling performance, stability in relevant biological media, and affinity/selectivity assessment using human post-mortem tissue and biofluids. Training includes analytical characterisation NMR/HPLC, digital pathology, image analysis and translational commercialisation. These are research categories, not a manufacturing protocol or promised human imaging trial.

The central feasibility gap is that recognising an aggregate in fixed tissue does not establish blood–brain-barrier access, intracellular target access, metabolic stability or interpretable whole-brain PET contrast. Binding to normal versus pathological protein, regional heterogeneity, co-pathology and non-specific background matter. An appropriate potential output could be a well-characterised candidate or a rigorous explanation of why a candidate fails a translation criterion. Neither successful brain imaging nor a clinical diagnostic product is guaranteed. A useful supervisor discussion is which evidence stage the four-year thesis must reach and which imaging expertise/resources are actually committed.

The competitive landscape has advanced beyond “a candidate just entering evaluation”. The NCT06891716 registry record, last updated 26 August 2026, listed the study as recruiting: an early-phase 1 study, with actual start 21 January 2025, estimated 45 participants, estimated completion November 2026, and no results posted. This is a dated study status, not a new check. This is the small-molecule ACI-19626, not the project's aptamer. Registered study and current status

AC Immune's 19 March 2026 sponsor release reports preliminary brain images and higher uptake in C9orf72-associated FTD than controls, with initial tolerability/pharmacokinetic observations. It is a company conference report, not independent diagnostic sensitivity/specificity, regulatory approval or evidence that every TDP-43 disease can be diagnosed. The aptamer route must justify a differentiated research contribution; it should not claim that all first-in-human imaging is still absent. Sponsor evidence, with its limits

School, Programme and Field Context

The degree-awarding institution is University of Aberdeen, United Kingdom, in the School of Medicine, Medical Sciences & Nutrition; EastBio is the training/funding partnership, not an Edinburgh degree for this project. The school offers a PhD and other distinct degrees, with PGR skills support and a viva voce. Exact portal registration designation and project-specific English band were not verified; the local email selection route below should not be replaced by Edinburgh's EUCLID instructions. The opportunity is four years, with part-time study available only to Home/UK students. Aberdeen doctoral environment

Original REF 2021 profiles give Aberdeen's Psychology, Psychiatry and Neuroscience submission 34% four-star/60% three-star overall, versus Clinical Medicine 15%/62%. They assess different subject submissions, not individual investigators or this tracer; an overall university ranking cannot settle radiochemistry fit. The imaging centre and neuroscience community are a more direct environment signal. Original dated subject assessment; Imaging context

EastBio training was restructured from the 2025 cohort: core research/professional/cohort activities focus on years 1–2, with greater research emphasis in years 3–4. Funded students normally complete a 12-week non-academic PIPS before the end of year 3, requiring planning and approval. Sector choice can include industry, policy, publishing or communication; no named company is guaranteed. Published 2026 cohort event dates should not be mistaken for this 2027 student's schedule. Current training; Placement requirement

Supervisors, Publications and Resource Boundaries

Sergio Dall'Angelo is a Lecturer and accepts PhD students, with institutional links to medical imaging and the Aberdeen Biomedical Imaging Centre. Jenna Gregory is currently a Professor/Clinical Chair, rather than merely the older Dr label, and studies neurodegenerative pathology. Chemistry and deeply phenotyped human tissue experience are complementary. Neither profile reveals supervision load, meeting frequency, radiochemistry technician availability or dedicated scanner time. Lead current role; Co-supervisor current role; Lab research context

Recent named-supervisor primary studies

Three core original papers and one additional original chemistry paper fall within the preceding five years. They are four distinct research articles, not four independent clinical validation cohorts: the 2024 study builds on the 2022 probe lineage, and the 2026 paper extends a regional ferritin question. Donor/cohort overlap has not been ruled out. Reviews, the patent and alternate versions are not counted as extra originals.

Spence and colleagues: tissue detection and its limits

Holly Spence; Fergal M. Waldron; Rebecca S. Saleeb; Anna-Leigh Brown; Olivia M. Rifai; Martina Gilodi; Fiona Read; Kristine Roberts; Gillian Milne; Debbie Wilkinson; Judi O’Shaughnessy; Annalisa Pastore; Pietro Fratta; Neil Shneider; Gian Gaetano Tartaglia; Elsa Zacco; Mathew H. Horrocks; Jenna M. Gregory. RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS. Acta Neuropathologica 147: 50. DOI: 10.1007/s00401-024-02705-1. published 2024-03-05; version_of_record 2024-03-05; accepted 2024-02-12.

Jenna M. Gregory is eighteenth/last of eighteen authors and co-corresponding with Mathew H. Horrocks; publisher equal-contribution note names Spence, Waldron, Horrocks and Gregory.

Human post-mortem evidence links early nuclear pathological change to loss-of-function signatures, before extensive cytoplasmic accumulation associated with clinical manifestation. This supports a distinct detection window; it is not prospective individual prediction or PET performance. De-identified slide images are available on reasonable request, not allocated automatically.

The archived research record reports a full publisher-HTML reading, with the complete article text retained. A later check covered the publisher abstract, full ordered byline and dates, contribution and correspondence notes, and selected Discussion; it was not a fresh full-paper or supplement review. Primary source

Zacco and colleagues: molecular recognition

Elsa Zacco; Owen Kantelberg; Edoardo Milanetti; Alexandros Armaos; Francesco Paolo Panei; Jenna Gregory; Kiani Jeacock; David J. Clarke; Siddharthan Chandran; Giancarlo Ruocco; Stefano Gustincich; Mathew H. Horrocks; Annalisa Pastore; Gian Gaetano Tartaglia. Probing TDP-43 condensation using an in silico designed aptamer. Nature Communications 13: 3306. DOI: 10.1038/s41467-022-30944-x. published 2022-06-23.

Jenna Gregory sixth of fourteen; credited data analysis and writing, not corresponding. Corresponding: Mathew H. Horrocks, Annalisa Pastore, Gian Gaetano Tartaglia. Zacco and Kantelberg equal contributors.

This original probe/super-resolution microscopy study supports molecular recognition and observation of condensates; it does not establish brain delivery or PET pharmacokinetics. Some computations remain restricted by patent/NDA arrangements although image/source data are provided; this project’s proprietary aptamer is not automatically the same published RNA probe.

The archived research record reports a full publisher-HTML reading, with the complete article text retained. A later check covered the abstract, ordered byline and date, author contributions and correspondence, and selected Discussion; it was not a fresh full-paper or supplement review. Primary source

Waldron and colleagues: regional iron associations

Fergal M. Waldron; Holly Spence; Orjona Stella Taso; Fiona L. Read; Irika R. Sinha; Katherine E. Irwin; Philip C. Wong; Jonathan P. Ling; Jenna M. Gregory. Brain iron as a surrogate biomarker of pathological TDP-43 identifies brain region-specific signatures in aging, and disease. Acta Neuropathologica Communications (early accepted publication). DOI: 10.1186/s40478-026-02433-5. published 2026-10-09; received 2026-05-31; accepted 2026-09-10.

Jenna M. Gregory ninth/last of nine, co-corresponding with Fergal M. Waldron. The early PDF credits Gregory conceptualization, primary funding, study leadership, analysis and writing. Waldron/Spence equal first contributors.

The publisher page labels this peer-reviewed accepted research as early and subject to replacement by a final Version of Record; no volume, issue or article/page range is assigned in the verified record. The reference PDF remains 22 pages and has duplicated Findings passages. The selected AD result 9 of 10 is not population prevalence; associations do not prove causality or a validated living-person MRI/PET surrogate. Selected discussion distinguishes molecular dysregulation in conventionally negative AD tissue from established LATE-NC. The stronger early-abstract variance claims are not adopted as settled findings.

The archived research file contains the 22-page early article-in-press PDF; its 69,546-character extracted text includes the version warning and duplicated Findings. The later targeted check covered the publisher abstract, byline/correspondence and version warning, plus selected Discussion, Tables 3–4 and author contributions. It was not a new full-PDF or supplement review; no final Version of Record was verified. Primary source

Charalambous and colleagues: related chemistry evidence

Nicolas Charalambous; Carina Schleidt; Rongfang Liu; Laura H. Heitman; Sergio Dall’Angelo; David O’Hagan; Phillip T. Lowe. A2A Adenosine Receptor Agonists With Last-Step Enzymatic 18F-Labelling Potential (Fluorinase) for Positron Emission Tomography (PET). European Journal of Organic Chemistry 29(5): e202501125. DOI: 10.1002/ejoc.202501125. early_online 2025-12-26; issue_date 2026-02-07.

Sergio Dall’Angelo fifth of seven, co-corresponding with David O’Hagan and Phillip T. Lowe.

The institutional record gives 8 pages; it supports related receptor-ligand chemistry, not a TDP-43 aptamer or demonstrated brain probe. Previous full-file requests returned 403, and the institutional record's final-version link was not opened. Evidence here is limited to the institutional record and abstract; no full-text review is claimed.

Primary source

The joint WO/2026/180736 patent record, published 3 September 2026, names both supervisors. Only metadata/abstract were read; it signals a real IP context, not clinical approval or proof that every patented reagent will be available. Ask about material access, publication review, ownership and thesis disclosure. Institutional imaging facilities and the lab's research links do not establish a reserved cyclotron/scanner slot, human-sample approvals or permissions for animal/human imaging. Joint IP record; Institutional facility scope

Funding, Costs and Application

This is a four-year competition, open to UK/international applicants with an overall 30% international recruitment cap. The 21 October partnership FAQ explicitly says successful international candidates will not be charged the overseas top-up tuition fee, so a mainland-China applicant should not be told that a known tuition gap must be self-funded. A selection/application is not a personal award; confirm the award letter and fee-status assessment. Current international fee-waiver commitment

The advert estimates £22,437 tax-free stipend for 2027/28, whereas UKRI guidance sets the 2026/27 minimum at £21,805. Preserve the former as an estimate, not an announced UKRI rate. Advertised research training support is £5,000/year for years 1–3, £1,500 in year 4 and travel/conference support £230/year: totals £16,500 training plus £920 travel over four years, not additional disposable salary. Visa and health surcharge are excluded. Confirmed reference-year UKRI standard; Excluded international costs

Aberdeen’s living-cost guidance recommends £1,171/month (£14,052/year) as a minimum planning reference associated with visa maintenance, not a guaranteed market budget. The £21,805 for 2026/27 is a dated UKRI reference; £22,437 for 2027/28 remains the project’s estimate. Neither establishes this applicant’s awarded income or personal surplus. Prepare a full annual budget for housing, uncovered contract weeks, immigration, relocation, dependants and exceptional travel; the overall planning reference already includes housing. Local budget and its scope

For 2026/27, South House washbasin rooms list £147/week, en-suite £191/week, with 40/41/50-week options. At 50 weeks these are £7,350/£9,550, requiring a plan for uncovered weeks; Wavell's £111/week is a 40-week option, not a year-round doctoral quote. Wi-Fi is included; the presence of laundry facilities does not establish free laundry. Confirm postgraduate room eligibility, commute to Foresterhill, utilities, contract and 2027 prices. Actual halls contracts

Published October 2026 figures list £558 for the visa and £776/year for student IHS, with upfront total based on visa duration and future rates. Outside-London financial evidence is £1,171 × up to 9 months = £10,539, plus relevant CAS fees; it is not a full-year living budget. China has differential documentary rules but funds must still be available and evidence may be requested; where applicable the holding rule is 28 days. Visa; IHS; Maintenance

Submission rules that affect selection

Contact the lead before applying. Local instructions require a single application email to smmsn-pgrenquiries@abdn.ac.uk, subject “EASTBIO Application – [Your Name]”, by 23:59 GMT, 16 November 2026. Include the completed EastBio form, university-level certificates/transcripts and two official-form references, one of which may be non-academic. References can accompany the application or be sent directly to the same address with “EASTBIO Reference – [Your Name]”; both must arrive by the same deadline.

The applicant must ensure receipt: the school will not chase omissions. Only one EastBio project may be selected, no research proposal is required, and unnecessary extra school certificates, papers or dissertations can cause exclusion. Processing acknowledgement may arrive after the deadline; all applicants are notified of the outcome. Do not import another university's later-reference concession.

The 21 October FAQ requires both referees to be outside the proposed supervisory team and non-English academic documents to include the original plus an official English translation. The central FAQ says extra documents such as a CV are disregarded, but this exact local advert warns that unnecessary extra documents can invalidate consideration; follow the stricter local checklist and do not add a CV or research proposal.

The EDI form and unique identifier requirements remain unconfirmed in the available application guidance and should be checked on the application form before submission.

Minimum qualification is a relevant UK 2:1 or international equivalent; a 2:2 may be considered with an obtained/expected master's Distinction or Commendation. Relevant here is not an advertised exhaustive subject list or a requirement to already master all listed techniques.

The 21 October FAQ also permits consideration of a master’s degree or significant relevant professional experience where a 2:1-equivalent undergraduate result is absent; the exact project states its more specific 2:2 plus master’s Distinction/Commendation route, so other exceptions require host confirmation.

The FAQ allows applying before an English test, with compliance potentially required before a formal offer; this does not establish a test waiver or this project’s numeric band. Exact Aberdeen degree equivalence, language band and subsequent registration remain to be confirmed.

The partnership timetable suggests supervisor nomination 18 January 2027, interviews week beginning 8 March, decisions week beginning 22 March, for October 2027 entry; these are central stages, not guaranteed individual interview/offer dates. Current application guidance; Central 2027 selection timetable

Fit and Preparation

The most relevant evidence connects chemistry/analytical measurements with critical interpretation of biological specificity. Chemistry, radiochemistry, medicinal chemistry, biochemistry or neuroscience preparation can support different parts of the project; this is an analytical fit profile, not a new formal degree requirement. The advert offers multidisciplinary training, so lack of prior use of every platform is not automatically disqualifying.

A compact prior-work example can explain how a signal was attributed to a target, how stability/background uncertainty was recognised, and where an inference stopped. A research discussion can contrast tissue recognition with living-brain imaging feasibility and explain how an informative negative result could remain a coherent thesis. It need not propose molecular sequences, radiolabelling recipes or animal procedures. Confirm whether the first-year emphasis is chemistry, analytical characterisation or tissue validation and how the complementary training will be delivered.

The proprietary material and existing human tissue are potential advantages only if access, approvals and training are in place. Nothing in the advert establishes personal clinical treatment responsibilities, an approved patient diagnostic service or guaranteed access to a clinical cohort.

Career directions

Transferable skills may support molecular-imaging R&D, analytical/radiochemistry, neuropathology and research careers. A UK clinical scientist is a regulated route: the Careers Service describes a three-year STP and HCPC registration, with a broad £49,000–65,000 career range and 38–40 hours/week. This research PhD does not automatically confer clinical registration, and those figures are not its graduates' salaries. No project-specific employment outcomes were verified. Career route and scope

Next Actions and Questions

Before applying: discuss fit with the lead, choose this as the single EastBio project if proceeding, organise both official-form references and resolve qualification/English assessment before the strict local deadline. Confirm the international fee waiver in the individual award and exact Aberdeen registration/start.

At interview: ask which aptamer and evidence stage are available, what permissions/IP govern use, how chemistry/pathology supervision is divided, which facilities and human samples are committed, and what achievable thesis endpoint applies if in-vivo translation fails. Establish daily training, meeting cadence and a feasible first-year result.

Before accepting: obtain stipend rate/duration, tuition coverage, research/travel allocations, material/publication rights and training/approval responsibilities in writing. Price a year-round housing contract, commute and upfront visa/IHS. The largest research uncertainty is the step from ex-vivo recognition to interpretable PET; the largest funding risk is winning the competition and bridging personal upfront costs, not an advertised unwaived overseas-fee top-up.

Evidence and Sources

This assessment uses EastBio recruitment material and FAQ captured in October 2026. The central application page and FAQ could not be accessed on 22 October, so application and fee-waiver details retain the scope of the 21 October records. Registry, sponsor, policy, cost and publication claims are dated to their cited materials; recruitment availability and clinical status have not been rechecked.

• Current EastBio 2027 recruitment and delegated project directory
• Current EastBio international eligibility and full fee waiver
• 2027 recruitment timetable and nomination sequence
• Current cohort training structure
• PIPS non-academic internship requirements
• Aberdeen SMMSN doctoral study and examination
• Aberdeen REF2021 original subject profiles
• Sergio DallAngelo current institutional profile
• Jenna Gregory current institutional profile
• Aberdeen Biomedical Imaging Centre
• Gregory laboratory research and output context
• Spence, Waldron et al. 2024 aptamer pathology study
• Zacco et al. 2022 TDP43 aptamer primary research
• Charalambous et al. 2026 radiochemistry study
• Waldron et al. 2026 accepted primary brain iron/TDP43 study
• Joint 2026 patent record: ownership and access implications
• Current registered ACI19626 early-phase imaging study
• AC Immune 19 March 2026 sponsor phase 1 report
• Aberdeen official living-cost planning guidance
• Aberdeen 2026/27 halls and contract costs
• UKRI confirmed reference rates
• Student visa fees
• Student IHS rate and duration basis
• Maintenance financial evidence and China document rules
• Clinical scientist role and regulated training route